ASH 2025

• Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B- cell lymphoma in real-life: A lysa Study from the descar-T registry,

Gabriel Brisou

 

• Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma

Karin Tarte

 

• Integrated clinico-biological profiling identifies a high-risk epigenetic signature in Mantle Cell Lymphoma: a LYSA Study

Morgane Cheminant

 

• Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Pierre Sesques

 

• Prognostic value of baseline metabolic tumor volume from LYSA Ro-CHOP trial in patients with previously untreated Peripheral T-Cell Lymphoma

Anne-Ségolène Cottereau

 

• CAR T-cell Therapy in Secondary CNS Lymphomas: A Real-world Study from the DESCAR-T Registry

Caroline Houillier

 

• Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Vincent Camus

 

• Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Tiy Morris

 

•  Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström’s Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström’s Macroglobulinemia (ECWM)

Pierre Morel

 

• Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial

Romain Guièze

 

• Treatment options, responses and outcome of 1220 classical Hodgkin lymphoma patients included in REALYSA, a prospective multicentric LYSA cohort

Hervé Ghesquières 

 

• Comparison of Axicabtagene Ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: a LYSA study from DESCAR-T and REALYSA registries

Gabriel Brisou

 

•  Impact of the Number of Bridging Therapy Lines on Outcomes After Axi-Cel in LBCL: A LYSA Study from the DESCAR-T Registry

Rémy Duléry

 

• Glofitamab Is Superior to Non a-CD3xC20 Treatments for Patients with Diffuse Large B-Cell Lymphoma Who Are Refractory or Relapse Immediately After Anti-CD19 CAR T-Cell Therapy: Final Results of the BiCAR Study (LYSA) and Indirect Comparison with a Synthetic Control Arm from the DESCART Registry

Pierre Sesques

 

•  Valemetostat Monotherapy in Patients with Relapsed or Refractory B-cell Lymphoma: Final Results of the Phase 2 VALYM Study from the LYSA

Emmanuel Bachy

 

• Center effect on large B-cell lymphoma outcome in frontline prospective phase II and III trials: a LYSA study

Tristan Robert-Van Houtteghem

 

• Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by LYSA

Gabriel Brisou

 

• Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from zuma-7 and alycante

Roch Houot

 

• Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: a study of the French DESCART registry

Stéphanie Guidez

 

• Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: a DESCAR-T analysis

Jean Galtier

 

• Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

Mikael Roussel

 

• Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A DESCAR-T and International Collaborative Study

Eric Durot

 

•  Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the RELEVANCE trial

Vincent Camus

 

•  Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Anne-Ségolène Cottereau

 

•  Glofitamab for Patients with Non–Large B-Cell Lymphoma Refractory or Relapsing after Anti-CD19 CAR T-Cell Therapy: Final BiCAR Study (LYSA) Results

Guillaume Cartron

 

•  MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with chronic lymphocytic leukemia

Caroline Croizier

 

• A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

Anne-Sophie Michallet